{"id":504903,"date":"2025-10-16T19:23:17","date_gmt":"2025-10-16T19:23:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/504903\/"},"modified":"2025-10-16T19:23:17","modified_gmt":"2025-10-16T19:23:17","slug":"scientists-create-cancer-vaccine-that-could-completely-stop-spread-of-disease","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/504903\/","title":{"rendered":"Scientists create cancer vaccine that could completely stop spread of disease"},"content":{"rendered":"<p>Researchers have developed a nanoparticle-based cancer vaccine that has been able to prevent multiple types of cancer in mice with the findings published in the prestigious Cell Reports Medicine<\/p>\n<p>11:58, 16 Oct 2025Updated 12:15, 16 Oct 2025<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/10\/0_Cancer-patient-speaking-to-a-doctor.jpg\" alt=\"Cancer patient speaking to a doctor\" loading=\"eager\"  \/>The nanoparticle-based vaccine was found to prevent multiple cancers (Image: GETTY)<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">A groundbreaking new study could pave the way for a \u2018next-generation\u2019 <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/all-about\/cancer\" target=\"_self\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">cancer <\/a>vaccine which has not only cleared existing <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/news\/health\/man-dies-11-months-after-36077206\" target=\"_self\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">tumours <\/a>but also completely prevented the disease\u2019s spread in some cases. Scientists from the <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.umass.edu\/news\/article\/umass-amherst-researchers-create-nanoparticle-vaccine-prevents-cancer-mice\" target=\"_blank\" aria-label=\"University of Massachusetts AmherstLink opens in a new tab.\" tabindex=\"0\" rel=\"noopener\">University of Massachusetts Amherst<\/a> revealed their findings in the journal <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(25)00488-4\" target=\"_blank\" aria-label=\"Cell Reports Medicine.Link opens in a new tab.\" tabindex=\"0\" rel=\"noopener\">Cell Reports Medicine.<\/a><\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">Looking at mouse models, their nanoparticle-based jab was able to <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/tv\/tv-news\/gb-news-star-shares-rare-36069889\" target=\"_self\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">prevent <\/a>melanoma, pancreatic and triple-negative breast cancer. The same jab can also shrink and clear <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/news\/health\/symptom-you-wake-up-morning-36035038\" target=\"_self\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">cancer tumours<\/a> alongside its preventative properties.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">88% of the vaccinated mice remained <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/all-about\/tumour\" target=\"_self\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">tumour<\/a>-free and while some had the spread of the disease reduced, others saw the cancer\u2019s spread completely stopped in its tracks. The experimental drug hasn\u2019t yet been trialled in humans.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">The \u201csuper adjuvant\u201d jab works similarly to the flu shot as it introduces weakened particles of the targeted disease into the body. The formulation of the vaccine then activates immune cells and primes them to recognise and attack these cancer cells.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/10\/0_Person-with-cancer.jpg\" alt=\"Person with cancer\" loading=\"lazy\"  \/>The drug hasn&#8217;t been trialled on humans yet(Image: GETTY)<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">The mice were given the jab and exposed to melanoma three weeks later. 80% of these mice remained tumour-free and survived until the end of the 250-day study.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">In comparison, mice that were unvaccinated or received traditional vaccine systems without nanoparticle formulations didn\u2019t survive for more than 35 days. When it comes to specific cancers, the tumour rejection rates for vaccinated mice were as high as 88% for pancreatic cancer, 75% for breast cancer and 69% for melanoma.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">Additionally, the vaccinated mice were also exposed to systemic cancer cells that mimic how cancer spreads across different parts of the body, known as metastasizing, targeting the lungs. None of them developed lung tumours, while all of the other mice did.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">This means that the vaccine could be making the immune system remember how it fought off the cancer cells in one area and use that information in another part of the body. Which is a key element of survival when facing cancer.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">Prabhani Atukorale, assistant professor of biomedical engineering in the Riccio College of Engineering at UMass Amherst and corresponding author on the paper said: \u201cBy engineering these nanoparticles to activate the immune system via multi-pathway activation that combines with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">Atukorale\u2019s previous research showed her novel nanoparticle-based drug design could shrink and clear cancer tumors in mice. This new study has now proven that it can also work to prevent cancer in the first place.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">The researchers say that their design offers a platform approach that could be used across multiple cancer types. They hope their findings can be applied to create both therapeutic and preventative programs for people at a higher risk of cancer.<\/p>\n<p class=\"Paragraph_paragraph-text__PVKlh \" data-tmdatatrack=\"content-unit\" data-tmdatatrack-type=\"paragraph\" publication=\"mirror\">Griffin Kane, postdoctoral research associate at UMass Amherst and first author on the paper added: \u201cThe real core <a class=\"TextLink_text-link__dBSS0 TextLink_enabled__dJF3l\" href=\"https:\/\/www.mirror.co.uk\/tech\/\" target=\"\" aria-label=\"\" tabindex=\"0\" rel=\"noopener\">technology<\/a> that our company has been founded on is this nanoparticle and this treatment approach.\u201d Next, Atukorale and Kane are already working on extending this technology to create a therapeutic vaccine.<\/p>\n","protected":false},"excerpt":{"rendered":"Researchers have developed a nanoparticle-based cancer vaccine that has been able to prevent multiple types of cancer in&hellip;\n","protected":false},"author":2,"featured_media":504904,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[1204,105,165551,16,15],"class_list":{"0":"post-504903","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-cancer","9":"tag-health","10":"tag-tumour","11":"tag-uk","12":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115385480479922195","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/504903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=504903"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/504903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/504904"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=504903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=504903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=504903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}